

Shelly J Krebs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7724860/publications.pdf>

Version: 2024-02-01

68
papers

2,441
citations

147726

31
h-index

233338

45
g-index

72
all docs

72
docs citations

72
times ranked

4086
citing authors

#	ARTICLE	IF	CITATIONS
1	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
2	HIV-1 infections with multiple founders associate with the development of neutralization breadth. <i>PLoS Pathogens</i> , 2022, 18, e1010369.	2.1	5
3	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 564-578.e9.	5.1	18
4	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	2.2	2
5	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. <i>Journal of Virology</i> , 2021, 95, e0079721.	1.5	2
6	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021, 374, 472-478.	6.0	228
7	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
8	Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. <i>STAR Protocols</i> , 2021, 2, 100771.	0.5	0
9	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	2.9	47
10	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021, 22, 1503-1514.	7.0	40
11	Preferential and persistent impact of acute HIV-1 infection on CD4 ⁺ iNKT cells in colonic mucosa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	2
12	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	2.9	94
13	Cerebrospinal fluid CD4 ⁺ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	2.1	9
14	Activated PD-1 ⁺ CD4 ⁺ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. <i>Aids</i> , 2020, 34, 197-202.	1.0	6
15	Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. <i>Aids</i> , 2020, 34, 415-426.	1.0	21
16	A high-throughput multiplex assay to characterize flavivirus-specific immunoglobulins. <i>Journal of Immunological Methods</i> , 2020, 487, 112874.	0.6	7
17	Determinants of suboptimal CD4 + T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25585.	1.2	13
18	HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. <i>Cell Reports</i> , 2020, 31, 107583.	2.9	60

#	ARTICLE	IF	CITATIONS
19	A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity. PLoS ONE, 2020, 15, e0231679.	1.1	7
20	Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment. Aids, 2020, 34, 1289-1301.	1.0	8
21	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nature Communications, 2020, 11, 272.	5.8	38
22	Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. Journal of the International AIDS Society, 2020, 23, e25444.	1.2	7
23	Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development. Frontiers in Immunology, 2020, 11, 621043.	2.2	16
24	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature Medicine, 2020, 26, 228-235.	15.2	61
25	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	2.1	13
26	Title is missing!. , 2020, 15, e0231679.		0
27	Title is missing!. , 2020, 15, e0231679.		0
28	Title is missing!. , 2020, 15, e0231679.		0
29	Title is missing!. , 2020, 15, e0231679.		0
30	Title is missing!. , 2020, 15, e0231679.		0
31	Title is missing!. , 2020, 15, e0231679.		0
32	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	2.9	36
33	Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. Journal of Infectious Diseases, 2019, 220, 1885-1891.	1.9	42
34	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV, the, 2019, 6, e297-e306.	2.1	73
35	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	6.6	77
36	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clinical Infectious Diseases, 2018, 66, 1540-1549.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 937-945.	1.9	15
38	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. <i>Journal of Infectious Diseases</i> , 2018, 218, 1453-1463.	1.9	28
39	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. <i>JCI Insight</i> , 2018, 3, .	2.3	16
40	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. <i>JCI Insight</i> , 2018, 3, .	2.3	32
41	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 108-117.	0.9	31
42	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. <i>Aids</i> , 2017, 31, 247-252.	1.0	21
43	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 124-131.	2.9	200
44	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	2.1	63
45	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	73
46	Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. <i>Journal of the International AIDS Society</i> , 2016, 19, 21163.	1.2	37
47	E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells. <i>BMC Microbiology</i> , 2016, 16, 152.	1.3	8
48	Immune activation during acute HIV infection and the impact of early antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 163-172.	1.5	56
49	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. <i>Journal of Immunology</i> , 2016, 196, 3064-3078.	0.4	56
50	Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. <i>Aids</i> , 2016, 30, 1533-1542.	1.0	44
51	Neurologic signs and symptoms frequently manifest in acute HIV infection. <i>Neurology</i> , 2016, 87, 148-154.	1.5	59
52	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. <i>Journal of Virology</i> , 2016, 90, 4005-4016.	1.5	25
53	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	45
54	Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. <i>Journal of Virology</i> , 2015, 89, 7478-7493.	1.5	33

#	ARTICLE	IF	CITATIONS
55	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47
56	Improvement of antibody responses by HIV envelope DNA and protein co-immunization. <i>Vaccine</i> , 2014, 32, 507-513.	1.7	35
57	Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits. <i>Journal of Virology</i> , 2014, 88, 12949-12967.	1.5	37
58	Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity. <i>Pharmaceutical Research</i> , 2014, 31, 2393-2403.	1.7	96
59	Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA. <i>PLoS ONE</i> , 2014, 9, e113463.	1.1	40
60	Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells. <i>PLoS ONE</i> , 2012, 7, e31464.	1.1	32
61	Protection and Attachment of <i>Vibrio cholerae</i> Mediated by the Toxin-Coregulated Pilus in the Infant Mouse Model. <i>Journal of Bacteriology</i> , 2011, 193, 5260-5270.	1.0	83
62	Crystal Structure of the <i>Vibrio cholerae</i> Colonization Factor TcpF and Identification of a Functional Immunogenic Site. <i>Journal of Molecular Biology</i> , 2011, 409, 146-158.	2.0	17
63	Nutrient-dependent, rapid transition of <i>Vibrio cholerae</i> to coccoid morphology and expression of the toxin co-regulated pilus in this form. <i>Microbiology (United Kingdom)</i> , 2011, 157, 2942-2953.	0.7	50
64	Genetic Mapping of Secretion and Functional Determinants of the <i>Vibrio cholerae</i> TcpF Colonization Factor. <i>Journal of Bacteriology</i> , 2009, 191, 3665-3676.	1.0	11
65	Characterization of a novel protective monoclonal antibody that recognizes an epitope common to <i>Vibrio cholerae</i> Ogawa and Inaba serotypes. <i>Microbiology (United Kingdom)</i> , 2009, 155, 2353-2364.	0.7	15
66	Perturbation of EGF-activated MEK1 and PKB signal pathways by TGF- β 1 correlates with perturbation of EGF-induced cyclin D1 and DNA synthesis by TGF- β 1 in C3H 10T1/2 cells. <i>Journal of Cellular Physiology</i> , 2000, 185, 107-116.	2.0	11
67	Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
68	Susceptibility to HIV-1 Acquisition linked to Malaria Exposure: A Case-control Study. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0